Cagrilintide, often studied in combination with semaglutide as CagriSema, is an amylin analog primarily investigated for weight management in individuals with obesity and type 2 diabetes. Semaglutide is a GLP-1 receptor agonist widely studied for similar indications, including weight loss and metabolic benefits. While Cagrilintide's standalone efficacy is less emphasized in our corpus, the combination therapy CagriSema consistently shows superior weight loss compared to semaglutide monotherapy, with some studies suggesting an average reduction of 22.5%. Both peptides are being explored for their potential in improving metabolic parameters and body composition.
| Cagrilintide | Semaglutide | |
|---|---|---|
| Drug class | amylin agonist | glp 1 agonist |
| Studies in corpus | 74 | 1011 |
| Highest evidence tier | meta analysis | — |
| Evidence tier mix | rct · 38 other · 7 review · 7 in vitro · 1 preclinical animal · 2 meta analysis · 2 | n/a |
| Studies with explicit sample size | 13 | 0 |
| Head-to-head studies in corpus | 0 — indirect comparison only | |
Beyond the literature: here's what third-party Certificate-of-Analysis records (Janoshik, BCC, Auxlabs) say about real Cagrilintide and Semaglutide batches we've tested. Aggregate, public data — cross-reference against the studies below.
We tested 756 Cagrilintide batches across 371 manufacturers, 99.52% avg purity.
We tested 941 Semaglutide batches across 307 manufacturers, 99.54% avg purity.
We hold deeper lab coverage on Semaglutide (941 batches tested). Semaglutide edges ahead on average measured purity (99.52% vs 99.54%) — a narrow gap; weigh it against failed-batch and underdose counts above.
Six head-to-head trials are present in our corpus, primarily evaluating CagriSema (a combination of cagrilintide and semaglutide) against semaglutide alone. These trials, including large Phase 3 studies, are designed to assess the potentially more potent effects of the combination therapy for obesity and type 2 diabetes, with extended treatment periods up to 72 weeks to gather robust efficacy and safety data. One Phase 1 trial specifically compared bioequivalence of different cagrilintide formulations (with placebo semaglutide) in overweight/obese adults. Studies also investigate optimal lower doses of CagriSema, such as 1.0 mg/1.0 mg or 1.7 mg/1.7 mg, to balance efficacy with tolerability. While Cagrilintide is often studied as part of the CagriSema combination, semaglutide has a much larger body of research (729 studies vs. 69 for cagrilintide), including meta-analyses exploring its link to non-arteritic anterior ischemic optic neuropathy risk and its potential in Parkinson's disease, though evidence for the latter is not consistently supportive. Semaglutide also has studies on oral formulations achieving equivalent exposure to subcutaneous doses and its synergistic effects with exercise for weight loss. The combination of cagrilintide and semaglutide is suggested to offer a more comprehensive approach to appetite regulation.
Looking for vendor-level purity, endotoxin, and HPLC data on Cagrilintide or Semaglutide? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.